How does the reported CDMO revenue growth compare to market expectations and previous quarters?

Scinai’s six‑month 2025 results show that CDMO (contract development and manufacturing organization) revenue jumped ≈ 30 % year‑over‑year, comfortably beating the consensus estimate of roughly 20 % that Wall Street was modelling into the model. The pace also marks a clear acceleration from the ≈ 12 % YoY increase recorded in the same period last year and from the single‑digit growth seen in Q4 2024, indicating that the CDMO platform is transitioning from a modest‑growth phase into a higher‑margin, scale‑up trajectory. Management highlighted new partnership wins in Europe and a stepped‑up capacity utilization that together drove the uplift.

From a trading standpoint, the beat on CDMO top‑line and the forward‑looking “balanced‑sheet” commentary have already pushed SCNI +4‑5 % in after‑hours trade, with the stock now testing the $4.70–$4.80 resistance zone. The bullish earnings surprise should keep short‑term buying pressure alive, especially as the technical picture shows a breakout above the 200‑day moving average and a bullish flag forming on the daily chart. However, investors should watch the next earnings guidance for CDMO volume and any signs of margin compression; a miss on the upcoming Q3 forecast could trigger a quick test of the $4.25 support line. In the near term, a buy‑on‑dip approach around $4.30–$4.40 with a target of $5.00 (the next resistance cluster) appears justified, while tighter risk control is warranted given the biotech sector’s volatility.